Pharvaris N.V. PHVS 深 滬
已收盤 12-24 16:00:00 美东时间
25.93
+0.080
+0.31%
華盛通- 最 高26.02
- 今 開25.74
- 成交量 5.71万股
- 最 低 25.56
- 昨 收 25.85
- 總市值 14.13亿
- 52周最高 29.797
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 11.51
- 委 比 81.82%
- 總股本 5449.31万
- 歷史最高 42.86
- 量 比 0.16
- 振 幅 1.78%
- 歷史最低 1.77
- 每 手 1
- 風險率 3.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
12-05 08:35
美股牛股 | 机器人概念股集体爆发！iRobot涨超73%，Richtech Robotics涨超18%；医药股Capricor暴涨超371%
机器人概念股集体爆发！iRobot涨超73%，Richtech Robotics涨超18%，特朗普新政拟All in 机器人；医药股Capricor暴涨超371%，关键实验获重大突破>>
12-04 15:42
Pharvaris' RAPIDe-3 Phase 3 Trial Of Deucrictibant For The On-demand Treatment Of Hereditary Angioedema Attacks Met The Primary Endpoint Of Median Time To Onset Of Symptom Relief, Achieved In 1.28 Hours, Significantly Faster Than Placebo
Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001)All secondary efficacy endpoints met (p<0.0001), including End of
12-03 19:56
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
Pharvaris GAAP EPS of -€0.60
Pharvaris press release (PHVS): Q3 GAAP EPS of -€0.60. Cash and cash equivalents were €329 million as of September 30, 2025, compared to €281 million for December 31, 2024. Research and Development (...
11-12 22:42
Pharvaris Q3 EPS $(0.64) Beats $(0.78) Estimate
Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.78) by 17.95 percent. This is a 24.71 percent increase over losses of $(0.85) per share from the
11-12 20:06
Pharvaris Presents Open-Label Prophylaxis Data Supporting Long-Term Safety Profile, Sustained Benefits Of Deucrictibant, And Clinical Validation Data Of Kinin Biomarker Assay, At ACAAI 2025
Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data of a kinin biomarker assay were highlighted in two oral presentationsFinal
11-10 19:53
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
Pharvaris, a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists, announced the acceptance of two abstracts for oral presentation and six for poster presentation at the ACAAI 2025 Annual Scientific Meeting in Orlando, FL. The oral presentations will discuss clinical validation of a kinin biomarker assay and long-term safety/efficacy of oral deucrictibant for HAE prophylaxis. Poster presentations will cover topi...
10-23 10:50
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
